Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Current Liabilities (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Total Current Liabilities data on record, last reported at $28.1 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 37.47% year-over-year to $28.1 million; the TTM value through Sep 2025 reached $28.1 million, up 37.47%, while the annual FY2024 figure was $21.0 million, 32.76% down from the prior year.
  • Total Current Liabilities reached $28.1 million in Q3 2025 per CAPR's latest filing, down from $28.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $37.1 million in Q1 2023 and bottomed at $3.0 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $21.1 million, with a median of $22.4 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 676.18% in 2022, then plummeted 37.81% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $4.1 million in 2021, then surged by 470.63% to $23.6 million in 2022, then skyrocketed by 32.57% to $31.3 million in 2023, then plummeted by 32.76% to $21.0 million in 2024, then soared by 33.87% to $28.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $28.1 million in Q3 2025, $28.4 million in Q2 2025, and $22.3 million in Q1 2025.